Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized Intrathecal Chemotherapy Based on Measurement of Brain Fluid Clearance in Pediatric Patients
2025-522453-20-00Phase 2Authorised
- Sponsor
- Oslo University Hospital
- Start
- Jul 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gadobutrol in acute lymphoblastic leukemia (ALL) and lymphoma, sponsored by Oslo University Hospital. Primary endpoint: Exploratory brain fluid clearance pharmacokinetic indices. Planned start Jul 2026; status: authorised.
02
Drugs
gadobutrol
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoma
Beyond the preview
Go deeper on 2025-522453-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522453-20-00.